Ozlem Aybuke Isik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ozlem Aybuke Isik has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Onur Cizmecioglu
Bilkent University
2 shared publications - Hazal Beril Çatalak Yılmaz
Department of Biological Sciences
1 shared publication - Mahnoor Sulaiman
Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
1 shared publication
Latest Publications
- Open Access
Tumor-Driven Innervation: Neoneurogenesis, Neural Mimicry, and Neuro-Immune Crosstalk in the Tumor Microenvironment
Cancer is increasingly understood as a tissue- and system-level disease shaped by dynamic interactions among malignant cells, stromal elements, the vasculature, the immune system, and the nervous system. In this context, tumors are not passive recipients of neural input, but active participants in the recruitment, remodeling, and exploitation of neural circuits that support tumor initiation, progression, metastasis, immune evasion, and resistance to therapy. Emerging work in cancer neuroscience has therefore shifted the field from a neuron-centric perspective toward an integrated model of the tumor microenvironment in which malignant cells help establish pathogenic neural niches. This review adopts a tumor-centric perspective to examine how cancer cells drive neoneurogenesis, engage in perineural invasion, and co-opt neural signaling and neuro-immune crosstalk to promote disease progression. It first distinguishes tumor-induced nerve growth and remodeling from perineural invasion as related but mechanistically distinct processes, then considers how tumor cell plasticity and neural mimicry enable malignant cells to acquire neuronal-like traits and exploit neural pathways. The review further explores how tumor-driven innervation shapes angiogenesis, immune modulation, therapeutic resistance, and minimal residual disease while also assessing emerging strategies designed to therapeutically target the tumor–nerve axis. By integrating these themes, the review highlights innervation not as a secondary feature of cancer, but as an active and potentially actionable dimension of tumor biology.
Open AccessTumor-Driven Innervation: Neoneurogenesis, Neural Mimicry, and Neuro-Immune Crosstalk in the Tumor Microenvironment
Cancer is increasingly understood as a tissue- and system-level disease shaped by dynamic interactions among malignant cells, stromal elements, the vasculature, the immune system, and the nervous system. In this context, tumors are not passive recipients of neural input, but active participants in the recruitment, remodeling, and exploitation of neural circuits that support tumor initiation, progression, metastasis, immune evasion, and resistance to therapy. Emerging work in cancer neuroscience has therefore shifted the field from a neuron-centric perspective toward an integrated model of the tumor microenvironment in which malignant cells help establish pathogenic neural niches. This review adopts a tumor-centric perspective to examine how cancer cells drive neoneurogenesis, engage in perineural invasion, and co-opt neural signaling and neuro-immune crosstalk to promote disease progression. It first distinguishes tumor-induced nerve growth and remodeling from perineural invasion as related but mechanistically distinct processes, then considers how tumor cell plasticity and neural mimicry enable malignant cells to acquire neuronal-like traits and exploit neural pathways. The review further explores how tumor-driven innervation shapes angiogenesis, immune modulation, therapeutic resistance, and minimal residual disease while also assessing emerging strategies designed to therapeutically target the tumor–nerve axis. By integrating these themes, the review highlights innervation not as a secondary feature of cancer, but as an active and potentially actionable dimension of tumor biology.
- Open Access
- 20 December 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 210-219
Class IA PI3K isoforms lead to differential signalling downstream of PKB/Akt
Objectives: The catalytic subunits of Class IA PI3K, p110α, p110β, and p110δ, phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) on the plasma membrane. In cancer, these catalytic subunits are usually found to be altered or amplified. Because pan-PI3K inhibition results in systemic toxicities, finding specific targets for the ubiquitous PI3K isoforms offers considerable potential for enhancing the effectiveness of PI3K-targeted therapy. Methods: We aim to delineate the isoform-specific druggable targets of the PI3K by deleting PIK3CA (encoding p110α) and PIK3CB (encoding p110β) by Cre mediated excision and ectopically expressing p110α, p110β, or p110δ with or without myristoylation (Myr) tag in mouse embryonic fibroblasts (MEFs). Myr is a lipidation signal that translocates proteins to plasma membrane permanently. This translocation renders p110s constitutively activated as they remain in close proximity to PIP 2 on the membrane. Results: Unique and redundant Akt targets are identified downstream of different PI3K isoforms. mTORC1, one of the targets of fully-activated Akt, has been observed to be differentially regulated in MEFs upon expression of p110α or p110β. The varying dependencies on mTORC1 and Rac1 led us to analyse a potential scaffolding function of p110β with Rac1 to mediate phosphorylation and activation of mTOR using platforms for the modeling of biomolecular complexes. We also documented that p110α and p110β support cell cycle kinetics differentially. Conclusions: This study suggests differential regulation of protein translation, metabolism, cell cycle, and survival signaling downstream of unique p110 targets, underlying the importance of cancer treatment according to the deregulated p110 isoform.
- 20 December 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 210-219
Open AccessClass IA PI3K isoforms lead to differential signalling downstream of PKB/Akt
Objectives: The catalytic subunits of Class IA PI3K, p110α, p110β, and p110δ, phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) on the plasma membrane. In cancer, these catalytic subunits are usually found to be altered or amplified. Because pan-PI3K inhibition results in systemic toxicities, finding specific targets for the ubiquitous PI3K isoforms offers considerable potential for enhancing the effectiveness of PI3K-targeted therapy. Methods: We aim to delineate the isoform-specific druggable targets of the PI3K by deleting PIK3CA (encoding p110α) and PIK3CB (encoding p110β) by Cre mediated excision and ectopically expressing p110α, p110β, or p110δ with or without myristoylation (Myr) tag in mouse embryonic fibroblasts (MEFs). Myr is a lipidation signal that translocates proteins to plasma membrane permanently. This translocation renders p110s constitutively activated as they remain in close proximity to PIP 2 on the membrane. Results: Unique and redundant Akt targets are identified downstream of different PI3K isoforms. mTORC1, one of the targets of fully-activated Akt, has been observed to be differentially regulated in MEFs upon expression of p110α or p110β. The varying dependencies on mTORC1 and Rac1 led us to analyse a potential scaffolding function of p110β with Rac1 to mediate phosphorylation and activation of mTOR using platforms for the modeling of biomolecular complexes. We also documented that p110α and p110β support cell cycle kinetics differentially. Conclusions: This study suggests differential regulation of protein translation, metabolism, cell cycle, and survival signaling downstream of unique p110 targets, underlying the importance of cancer treatment according to the deregulated p110 isoform.